282 reports of this reaction
3.2% of all OXYMETAZOLINE HYDROCHLORIDE reports
#3 most reported adverse reaction
ANOSMIA is the #3 most commonly reported adverse reaction for OXYMETAZOLINE HYDROCHLORIDE, manufactured by Bayer HealthCare LLC.. There are 282 FDA adverse event reports linking OXYMETAZOLINE HYDROCHLORIDE to ANOSMIA. This represents approximately 3.2% of all 8,811 adverse event reports for this drug.
Patients taking OXYMETAZOLINE HYDROCHLORIDE who experience anosmia should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
ANOSMIA is moderately reported among OXYMETAZOLINE HYDROCHLORIDE users, representing a notable but not dominant share of adverse events.
In addition to anosmia, the following adverse reactions have been reported for OXYMETAZOLINE HYDROCHLORIDE:
The following drugs have also been linked to anosmia in FDA adverse event reports:
ANOSMIA has been reported as an adverse event in 282 FDA reports for OXYMETAZOLINE HYDROCHLORIDE. This does not prove causation, but indicates an association observed in post-market surveillance data.
ANOSMIA accounts for approximately 3.2% of all adverse event reports for OXYMETAZOLINE HYDROCHLORIDE, making it one of the most commonly reported side effect.
If you experience anosmia while taking OXYMETAZOLINE HYDROCHLORIDE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.